

(12) INTERNATIONAL APP'

PATENT TREATY (PCT)

**(19) World Intellectual Property Organization
International Bureau**



(43) International Publication Date
18 January 2001 (18.01.2001)

PCT

(10) International Publication Number
WO 01/04335 A2

- (51) International Patent Classification⁷: C12N 15/86.
7/04. C07K 14/14, C12N 15/62, A61K 38/17

(21) International Application Number: PCT/US00/17755

(22) International Filing Date: 24 June 2000 (24.06.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/143,132 9 July 1999 (09.07.1999) US

(71) Applicant (*for all designated States except US*): THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE DEPARTMENT OF HEALTH AND HUMANSERVICES [US/US]; 6011 Executive Blvd., Suite 325, Rockville, MD 20852 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): BUCHHOLZ, Ursula [DE/DE]; Boddenblick 10, D-17498 Insel Riems (DE). COLLINS, Peter, L. [US/US]; 12304 Village Square #401, Rockville, MD 20852 (US). MURPHY, Brian, R. [US/US]; 5410 Tuscawaras Road, Bethesda, MD 20816 (US). WHITEHEAD, Stephen, S. [US/US]; 7 Prairie Rose Lane, Gaithersburg, MD 20878 (US). KREML, Christine, D. [DE/US]; 12512 Village Square Terrace, Spt. 102, Rockville, MD 20852 (US).


(74) Agents: KING, Jeffrey, J. et al.; Townsend and Townsend and Crew LLP, Two Embarcadero Center, 8th floor, San Francisco, CA 94111-3834 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian

[Continued on next page]

(54) Title: PRODUCTION OF ATTENUATED, HUMAN-BOVINE CHIMERIC RESPIRATORY SYNCYTIAL VIRUS VACCINES



nucleotide modifications are provided within the human-bovine chimeric RSV of the invention to yield desired phenotypic and structural effects.